Related references
Note: Only part of the references are listed.Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer
Laura A. Huppert et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2023)
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
Chiara Corti et al.
CANCER TREATMENT REVIEWS (2023)
An emerging generation of endocrine therapies in breast cancer: a clinical perspective
Rima Patel et al.
npj Breast Cancer (2023)
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
Hope S Rugo et al.
LANCET (2023)
Development of novel agents for the treatment of early estrogen receptor positive breast cancer
Mitchell J. Elliott et al.
BREAST (2022)
HER2-Low Breast Cancers New Opportunities and Challenges
Huina Zhang et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2022)
KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A phase IB/II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer (KCSG BR18-16).
Se Hyun Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC)
M. P. Goetz et al.
ANNALS OF ONCOLOGY (2022)
Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2-locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study
M. Martin Jimenez et al.
ANNALS OF ONCOLOGY (2022)
Accelerating drug development in breast cancer: New frontiers for ER inhibition
Emanuela Ferraro et al.
CANCER TREATMENT REVIEWS (2022)
Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer
Xinlin Liu et al.
PHARMACOLOGY & THERAPEUTICS (2022)
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
Erika Hamilton et al.
CLINICAL BREAST CANCER (2021)
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
A. Gennari et al.
ANNALS OF ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Pembrolizumab plus eribulin in hormone receptore-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial
Jose M. Perez-Garcia et al.
EUROPEAN JOURNAL OF CANCER (2021)
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer A Randomized Clinical Trial
Antonio Llombart-Cussac et al.
JAMA ONCOLOGY (2021)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
D. J. Slamon et al.
ANNALS OF ONCOLOGY (2021)
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer
Yuan Yuan et al.
EUROPEAN JOURNAL OF CANCER (2021)
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2 A Randomized Clinical Trial
George W. Sledge et al.
JAMA ONCOLOGY (2020)
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer
Ami N. Shah et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: fi nal results from a phase I/II, single-arm, basket trial
K. Kalinsky et al.
ANNALS OF ONCOLOGY (2020)
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial
Sara M. Tolaney et al.
JAMA ONCOLOGY (2020)
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M. E. Robson et al.
ANNALS OF ONCOLOGY (2019)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston et al.
NPJ BREAST CANCER (2019)
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
G. N. Hortobagyi et al.
ANNALS OF ONCOLOGY (2018)
PARP Inhibitors in Breast Cancer: Bringing Synthetic Lethality to the Bedside
Anita A. Turk et al.
CANCER (2018)
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
Hitisha K. Patel et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
Marc Thill et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations
Laura M. Spring et al.
ONCOLOGIST (2017)
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer
Susan Combs Scott et al.
SEMINARS IN ONCOLOGY (2017)
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial
Sarat Chandarlapaty et al.
JAMA ONCOLOGY (2016)
Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins
Rohit Prakash et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2015)
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
F. Cardoso et al.
BREAST (2014)
Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review)
Mei Hong Zhang et al.
BIOMEDICAL REPORTS (2014)
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
Denise A. Yardley et al.
ADVANCES IN THERAPY (2013)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
William R. Miller et al.
ONCOLOGIST (2008)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
